BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA. TD Cowen 46th Annual Health Care ConferenceFormat: ...

Core Insights - Elicio Therapeutics has appointed Marc J. Wolfgang as Chief Technology Officer, bringing over 30 years of biopharmaceutical leadership experience [1][2][3] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers [4] - The company aims to leverage its Amphiphile ("AMP") technology to enhance cancer-specific T cell responses, promoting durable cancer immunosurveillance [4] - Elicio's lead program, ELI-002, targets common KRAS mutations found in approximately 25% of all solid tumors and is currently in a randomized clinical trial for mKRAS-positive pancreatic cancer [4] Leadership and Expertise - Marc J. Wolfgang has extensive experience in manufacturing, CMC strategy, and operations across various modalities, including cell therapy and RNA-based medicines [2][3] - His previous roles include Senior Vice President at Sail Biomedicines and Vice President of U.S. Manufacturing at BioNTech, where he oversaw critical manufacturing and supply chain operations [2] Strategic Goals - The company is preparing for late-stage development and commercial-scale execution of ELI-002, with a primary disease-free survival analysis expected in the first half of 2026 [3] - Elicio plans to expand ELI-002 to other indications, including mKRAS-positive lung cancer, and is developing additional off-the-shelf immunotherapy candidates targeting BRAF-driven cancers and p53 hotspot mutations [4]

Core Insights - Elicio Therapeutics has granted inducement awards to its newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional employees as part of their employment agreement [1][2] - The inducement awards consist of 191,624 stock options for Dr. Shah and a total of 21,000 stock options for the other two employees, with an exercise price of $4.98 per share [2] - The stock options will vest over four years, with 25% vesting on the first anniversary of the respective start dates and the remainder vesting monthly thereafter [3] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers [4] - The company aims to leverage its Amphiphile ("AMP") technology to enhance the activation of cancer-specific T cells, promoting durable cancer immunosurveillance [4] - Elicio's lead program, ELI-002, targets common KRAS mutations found in approximately 25% of all solid tumors and is currently in a randomized clinical trial for patients with mKRAS-positive pancreatic cancer [4]